Skip to content

A Pilot Study for the Evaluation of the Safety and Performance of a Combined OCT System

A Prospective,Open Label,Non-randomized,Single-centre,Exploratory,Stratified Pilot Study for the Evaluation of the Safety and Performance of a Combined Coaxial Optical Coherence Tomography (OCT) System,to Image Diseases of the Posterior and Anterior Segment of the Eye

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03419390
Acronym
Hydra01
Enrollment
30
Registered
2018-02-05
Start date
2016-12-01
Completion date
2019-12-31
Last updated
2020-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

Hydra01

Brief summary

The novel Coaxial Optical Coherence Tomography (OCT) System is designed to visualize both structures of the retina and choroid. The purpose of this research is the safety and evaluation of a combined coaxial optical coherence tomography (OCT) system, to image diseases of the posterior and anterior segment of the eye.

Detailed description

Background and Rationale: Many posterior segment ocular diseases involve the retinal and choroidal vasculature. A new technology to noninvasively and simultaneously visualize vascular pathology is of utmost importance to reduce patient exposure to different diagnosis methods like e.g. fluorescence angiography. The novel Coaxial Optical Coherence Tomography (OCT) System is designed to visualize both structures of the retina and choroid. Furthermore, it may be used to image other structures of the eye. Objective(s): The purpose of this research is the safety and evaluation of a combined coaxial optical coherence tomography (OCT) system, to image diseases of the posterior and anterior segment of the eye. This device may be useful for the early diagnosis and monitoring of a variety of diseases involving the eye, such as Glaucoma, Diabetic Retinopathy or Age-Related Macular Degeneration. Measurements are compared to normal controls. Measurements and procedures: After screening, all participants will undergo a scanning procedure on the same day. Only one eye of each participant will be scanned with the investigational device. For patients, the eye showing the disease will be chosen, for healthy volunteers, the left or right eye will be scanned according to a randomisation list. The image quality is rated by the investigator and an independent assessor on a VAS (visual analogue scale). A subgroup of each stratum will have a comparative measurement of the choroid thickness against a SS-OCT (swept-source-OCT) device (Topcon) and a retina thickness against the Spectralis data. The subgroup will consist of half planned sample size. The measurement is taken from one eye, ie. every second participant per stratum will be attributed to the thickness measurement subgroup. The endpoint is a true/false criterion on whether the measurement of the retina and choroid thickness was successful. The thickness is measured in μm. The measurement is considered a success if the value is no more than +/- 10% off the reference measurement.

Interventions

DEVICEcombined Coaxial Optical Coherence Tomography (OCT) System

The investigational device is an OCT scanner prototype with two different wavelengths developed based on a CE marked OCT device (Spectralis® Heidelberg) at the Berner Fachhochschule, Biel

Sponsors

University Hospital, Basel, Switzerland
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Proof of concept study, medical device investigation

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Subjects with healthy eye, or has been diagnosed already with eye disease * Patients \> 18 years of age * Informed Consent as documented by date and signature

Exclusion criteria

* Clinically significant concomitant disease that impair measurement * Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, late stage Alzheimer disease, etc. of the participant, * Subjects using implanted electronic medical devices (e.g. cochlear implant, pacemaker, defibrillator, infusion pump). * Participation in another study with investigational drug within the 30 days preceding and during the present study

Design outcomes

Primary

MeasureTime frameDescription
Visual acuity (VA) after investigationWithin 1 hour after investigationSafety of the imaging investigation expressed as visual acuity before (baseline) and after imaging, and tolerability assessment questionnaire.

Secondary

MeasureTime frameDescription
Scan qualityAfter completion of all measurement, an average of 2 years.Comparing scan quality of investigational device to scan quality of a reference device, expressed as thickness of the retina and the thickness of the choroid
Procedural successAfter completion of all measurement, an average of 2 years.Procedural success that is defined as: Image Quality of anterior and posterior eye structures
Procedural safety and comfort assessed by questionnaireWithin 1 hour after investigationProcedural comfort in the opinion of the patients assessed with a questionnaire

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026